International Journal of Nanomedicine, Год журнала: 2024, Номер Volume 19, С. 9821 - 9841

Опубликована: Сен. 1, 2024

Renal cell carcinoma (RCC) is the most common and lethal type of urogenital cancer, with one-third new cases presenting as metastatic RCC (mRCC), which, being seventh cancer in men ninth women, poses a significant challenge. For patients poor prognosis, temsirolimus (TEM) has been approved for first-line therapy, possessing pharmacodynamic activities that block growth inhibit proliferation-associated proteins. However, TEM suffers from water solubility, low bioavailability, systemic side effects. This study aims to develop novel drug formulation treatment RCC.

Язык: Английский